Syngene International has announced an additional investment of up to $56 million in its wholly-owned US subsidiary, Syngene USA Inc. The move includes acquiring a facility from Emergent Manufacturing Operations Baltimore, LLC for $36.5 million, with the remaining funds allocated for making the facility operational. This expansion aims to enhance its capabilities in serving both human and animal health market segments. The transaction is expected to close by March 2025, subject to regulatory approvals.
Also read: Bharat Electronics Secures ₹843 Crore in New Defence Orders
Key takeaways
Investment amount: Syngene International to invest $56 million in Syngene USA Inc.
Facility acquisition: Acquiring the Baltimore-based facility for $36.5 million.
Operational costs: An estimated $50 million will be spent on facility setup, including acquisition and expenses.
Market expansion: Strengthening presence in human and animal health sectors.
Syngene International share price: Closed at Rs 678 on BSE, down 0.22% on Monday.
Also read: Aditya Birla Capital Infuses ₹300 Crore into Housing Finance Subsidiary via Rights Issue
Financial breakdown of the investment
Syngene International’s investment includes both the acquisition cost and expenses for making the facility fully operational. The move aligns with the company’s strategy of expanding its US footprint to meet growing market demands.
Investment category
| Amount (in USD)
|
Facility acquisition
| $36.5 million
|
Operational expenses
| $19.5 million
|
Total investment
| $56 million
|
Strategic expansion in the US market
The acquisition of the Baltimore facility is part of Syngene International’s long-term strategy to expand its contract research, development, and manufacturing services in the US. The facility will cater to both pharmaceutical and biotechnology clients, improving the company’s ability to serve international markets efficiently.
With this move, Syngene International aims to strengthen its contract development and manufacturing organisation business, which has been a key growth driver. The additional investment will help the company enhance its infrastructure and meet rising demand from the human and animal health segments.
Syngene International’s decision to invest $56 million in its US subsidiary reflects its commitment to expanding global operations. The acquisition of the Baltimore facility will enhance its research and manufacturing capabilities, positioning it as a stronger player in the market. Investors will be closely monitoring Syngene International share price, as the investment is expected to drive future growth and strengthen its global presence.
Also read: Sun Pharma to Acquire Checkpoint Therapeutics for $355 Million
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer